Objective. According to our previous studies, ghrelin protects blood brain barrier (BBB) integrity and it attenuates hypoxia-induced brain edema in the hypoxic conditions. However, the underlying mechanisms remain poorly understood. Several studies suggest a role for matrix metalloproteinase-9 (MMP9) in the BBB disruption and cerebral edema formation. The present study was conducted to determine the effect of ghrelin on MMP9 protein expression in the model of acute and chronic systemic hypoxia.
that ghrelin, as an anti-inflammation, neuroprotection and anti-apoptosis agent, reduces cerebral injuries in animal models (Brywe et al. 2005; Liu et al. 2006; Miao et al. 2007; Chung et al. 2008; Andrews 2011) . In addition, in previous studies, we and others have shown that ghrelin treatment ameliorates blood brain barrier (BBB) disruption and attenuates cerebral edema, in which ghrelin acts via decrease of the inflammatory cytokines expression such as TNF-α, interleukin (IL)-1β, IL-6 and vascular endothelial growth factor (VEGF) and it also inhibits the degradation of tight junction proteins such as zonula occludens-1( ZO-1) and occludin in several experimental models including subarachnoid hemorrhage, traumatic brain injury, and systemic hypoxia (Bansal et al. 2010; Ersahin et al. 2010; Hossienzadeh et al. 2013; Mohaddes et al. 2015 Mohaddes et al. , 2017 .
There are also evidences that ghrelin reduces myeloperoxidase activity, neutrophil trafficking, nitric oxide synthase (nNOS), as well as matrix metalloproteinase-9 (MMP9) in spinal cord injury and middle cerebral artery occlusion (MCAO) models (Cheyuo et al. 2011; Zhang et al. 2012) . Huang et al. (2009) have indicated in their research that ghrelin has a protective effect against myocardial infarction in rats, through reducing MMP9 expression. Recently, it has been reported that administration of ghrelin immediately after spinal cord injury (SCI) considerably protects the disruption of the blood spinal cord barrier (BSCB) and hemorrhage via down-regulation MMP9 (Lee et al. 2014) .
The MMP9 is a member of the MMPs family (Sato et al. 1996) that is expressed in brain at relatively low levels under physiologic conditions (Cunningham et al. 2005 ). However, MMP-9 expression increased in a very large number of brain pathologies, including cerebral ischemia, traumatic brain injury, and hypoxic brain that cause BBB disruption and cytotoxic and vasogenic brain edema formation (Yang et al. 2007; Rosenberg 2009; Bauer et al. 2010; Duran-Vilaregut et al. 2011; Higashida et al. 2011) .
To our knowledge, only a few reports have shown the effects of ghrelin on MMP9 protein following experimental cerebral damages and no study, to date, has reported its effects in hypoxic brain. Therefore, the present study aimed to evaluate the effect of ghrelin on MMP9 protein levels in the hypoxic brain that was induced by systemic acute and chronic hypoxia in the rats.
Materials and methods
Animals and experimental groups. Adult male Wistar rats (235±15 g) were purchased from the Tabriz University of Medical Sciences and housed in standard cages in a temperature (22-24°C), humidity (40-60%), and light period (12-h light/dark cycle) controlled environment. Food and water were available ad libitum. Experiments were performed in conformity with the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23 revised 1985) and were approved by the research and ethics committee of the Tabriz University of Medical Sciences(No: 89/4-13/11).
The rats (n=36) were randomly divided into six groups (n=6), including acute or chronic control groups, acute or chronic hypoxia and ghrelin-treated acute or chronic hypoxia groups. Control and hypoxic (acute and chronic) groups received saline (1 ml/kg, i.p., daily). Ghrelin-treated acute and chronic hypoxic groups received acylated ghrelin (Innovagen, Sweden) at a dose of 80 μg /kg, i.p., daily for 2 or 10 days, respectively (Hossienzadeh et al. 2013) .
Induction of acute and chronic systemic hypoxia. Control groups were kept in room air (21% O 2 ). Acute and chronic systemic hypoxia (10-11% O 2 ) were induced in the hypoxic chamber (GO2 AltitudeBiomedical, Australia). Acute and chronic hypoxic groups were kept in the chamber all the time for 2 and 10 days, respectively; except for cleaning the cages and daily injections.
Western blot analysis. For studying western blot, the rats were sacrificed after anesthetizing by an overdose of sodium pentobarbital (100 mg/kg), the brains immediately were removed and frozen in liquid nitrogen. Then, the brain samples were homogenized as described previously (Mohaddes et al. 2015) . Equal amounts of samples (20 μg protein) were electrophoretically separated on 10% SDS-PAGE gels. The lysates were transferred to polyvinylidene difluoride (PVDF) membranes, blocked with 5% milk and incubated 90 min or 1 h at room temperature with primary antibodies against MMP9 (Abcam, Cat # ab76003) and beta actin (Abcam, Cat # 8227), diluted 1:1000 and 1:5000 in blocking solution, respectively. Followed by washing, incubation with an HRP-conjugated secondary antibody diluted 1:3000 in 5% milk/PBS-T for 1 h at room temperature and more washing; the blots were imagined with the enhanced chemiluminescence (ECL) detection kit for 1 min and then exposed to hyper film for 60 s to 10 min. Finally, the films were scanned, and the density of the immunoreactive bands was determined by Image J software and normalized to the bands of the internal control (beta-actin).
Statistical analysis. (Figure 2) .
Effects of acute and chronic systemic hypoxia and ghrelin administration on MMP9 protein level in the hypoxic brain. The acute and chronic systemic hypoxia significantly increased the MMP9 protein expression in comparison with the acute and the chronic control groups (p<0.001). Administration of ghrelin significantly decreased the expression of MMP9 in both the acute and chronic hypoxic groups (p<0.05). In addition, the MMP9 expression was significantly different between the acute hypoxic (AH) and the chronic hypoxic (CH) groups (p<0.001). Also, the MMP9 expression significantly changed between the ghrelin-treated acute hypoxic group (AH+G) and the ghrelin-treated chronic hypoxic group (CH+G) (p<0.001). The expression of MMP9 did not change in both the acute and chronic control groups (p>0.05) (Figure 3 ).
Discussion
Our previous studies have shown that treatment of ghrelin attenuates hypoxia-induced brain edema along with decreasing TNF-α and VEGF proteins levels and it also inhibits the degradation of tight junction proteins such as ZO-1 and occludin in the hypoxic brain (Hossienzadeh et al. 2013; Mohaddes et al. 2015 Mohaddes et al. , 2017 . But, the neuroprotective effects mechanisms of ghrelin are not completely clear in the hypoxic conditions. Therefore, in the present study we investigated the effect of ghrelin on MMP9 protein level in the hypoxic brain. Results of the present study showed that systemic administration of ghrelin significantly reduces MMP9 protein level in the hypoxic brain following acute and chronic systemic hypoxia.
Our results are in accordance with recent work showing a neuroprotective effect of ghrelin on blood spinal cord barrier disruption, by down-regulating MMP9 following traumatic spinal cord injury in rats (Lee et al. 2014) . Furthermore, our results are consistent with other study showing a decreased production in MMP9 protein level following treatment of ghrelin in myocardial infarction in rats (Huang et al. 2009 ).
There are evidences that in the central nervous system, more activation and MMP9 protein expression play a key role in the degradation of the extracellular matrix, tight junction proteins inducing vascular permeability in the ischemic, hypoxic brain, and traumatic spinal cord injury models (Yang et al. 2007; Rosenberg 2009; Bauer et al. 2010; Duran-Vilaregut et al. 2011; Higashida et al. 2011) . Several studies have shown that inhibition of MMP-9 protein expression and its activation significantly decreases blood brain barrier damage, brain vessels leakage, and infarct size in several animal models (Wang et al. 2000; Asahi et al. 2001; Gasche et al. 2001) .
Underlying mechanisms of ghrelin on activation and the MMP9 protein expression have not been elicited yet. Several studies have demonstrated that the inflammatory cytokines such as TNF-α and excess free radicals increase expression and activation of MMP9 (Vecil et al. 2000; Bond et al. 2001; Duansak and Schmid-Schonbein 2013) . Several studies have also reported that MMP9 activity is associated with VEGF release (Belotti et al. 2003; Reszec et al. 2015) . Furthermore, according to a study by Wang and Keiser (1998), VEGF stimulates the secretion of MMPs from vascular smooth muscle cell (SMC). Since our previous studies have shown that ghrelin decreases synthesis of TNF-α and VEGF protein levels (Hossienzadeh et al. 2013; Mohaddes et al. 2015) and it also has an antioxidant and free radical scavenger activities in the hypoxic brain (Kheradmand et al. 2010) . It is more probably that the effect of ghrelin on MMP9 protein expression might be related to its inhibitory effects on TNF-α, VEGF levels as well as antioxidant activity in the hypoxic condition. Furthermore, our recent study has reported that treatment of ghrelin inhibits degradation ZO-1 and occludin, tight junction proteins, in the hypoxic brain. In fact, the anti-edematous effect of ghrelin observed in our previous study is likely related to, at least in part, the inhibition of the production of MMP9 protein and its activity in the hypoxic brain. Although, in the present study the effect ghrelin on MMP9 activation was not determined, others studies have revealed that ghrelin treatment attenuates MMP9 activation (Huang et al. 2009; Lee et al. 2014 ).
In addition, it was shown that chronic hypoxia significantly increases the erythropoietin (EPO) plasma level in rats but ghrelin treatment decreases both plasma EPO and EPO gene expression in the hypoxic rats (Feizi et al. 2014 ). On the other hand, EPO inhibited expression of TNF-α and MMP9 during ischemiareperfusion injury ) as well as pro-inflammatory cytokines in rodent brains during oxygen toxicity (Sifringer et al. 2009 ). Besides, the EPO regulates vascular smooth muscle cells proliferation and migration (Park et al. 2015) . Although in the present study, we did not measure plasma EPO level and gene expression, Feizi et al. (2014) have shown that ghrelin administration decreases both plasma EPO levels and gene expression in the chronic hypoxic condition. It seems that our present finding is in disagreement with studies showing effects of the EPO on decreasing expression of TNF-α and MMP9 as well as proinflammatory cytokines in the several animal models (Sifringer et al. 2009; Wu et al. 2009 ). Although the reason for this discrepancy is not clear, it may be related to the experimental design, methodology or differences in the underlying mechanisms of the EPO during ischemia-reperfusion injury and oxygen toxicity versus the acute and chronic systemic hypoxia.
Therefore, we suggest that decrease of the MMP9 protein level and its activation following ghrelin injection is more likely done through the decreasing inflammatory factors, their signaling pathways, and free radicals as well as VEGF protein consequently, the protection of the BBB against damage in during systemic hypoxia. More studies are needed to elucidating these possibilities. In conclusion, we propose that the neuroprotective effects of ghrelin, in part, must be mediated by decreasing the MMP9 production in the hypoxic brain. Moreover, ghrelin may be a new therapeutic strategy for the treatment of hypoxia-induced brain edema.
